Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vestas receives 224 MW order in USA

News release from Vestas-American Wind TechnologyPortland, 13 December 2019 Vestas has received an order for 224 MW of V120-2.2 MW wind turbines for a wind project in the U.S. The order includes supply and commissioning of the turbines as well as a 10-year service agreement, designed to ensure optimised performance for the lifetime of the project. Turbine delivery will begin in the second quarter of 2020 with commissioning scheduled for the fourth quarter of 2020. The project and customer are undisclosed. For updated Vestas photographs and videos, please visit our media images

Holiday magic with Hybrid Steel

What better way to capture the magic of Holiday season than with a magical new steel? Because that is how we think of our Hybrid Steel, a groundbreaking innovation made possible by a new alloying philosophy and a sophisticated hybrid hardening metallurgy.Until now, the world of steel has been divided into clearly separated categories – the specialist tool steels, maraging steels and stainless steels and the more common engineering steels. That has always meant that steel selection was a compromise between the desire for high performance and the demand for production economy. But now there

Read original

2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019.

2cureX AB (“2cureX”, NASDAQ: 2CUREX) announces that the company presented significant progression of the IndiTreat® test for individualizing immuno-oncological treatment at the ESMO IO Congress. This development project is funded by the German Federal Ministry of Education and Research and is conducted in collaboration with the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, UKE).Immuno-oncology (I-O) therapy for different types of cancer has contributed significantly to the cancer treatment landscape and is among the fastest growing areas within

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release December 13, 2019, at 9:45 a.m. Nokian Tyres has received an announcement from Bridgestone Corporation on December 13, 2019, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement Bridgestone Corporation’s direct holding in Nokian Tyres shares fell below the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on December 12, 2019. The direct shareholding was 4,167,653 shares, representing 3.00% of Nokian Tyres’ 138,921,750 shares and voting rights.

Idogen files patent application for new tolerogenic cell therapy

Idogen AB (Spotlight Stock Market: IDOGEN) announced today that the company has filed a patent application for its new, innovative method for cell therapy. The method is based on a unique combination of tolerance-inducing substances that have shown good results in preclinical trials. The patent application covers Idogen’s entire technology platform for tolerogenic cell therapy and the application provides a right of priority and is a first step towards a global expansion to all major markets. Granting will provide market exclusivity until 2040.Idogen’s tolerogenic dendritic cells are

Hansa Biopharma has agreed with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S.

Lund, Sweden December 13, 2019 Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced the outcome of a November 20th meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients. Upon agreement with the FDA, following submission of a final study protocol, the Company will conduct a randomized, controlled clinical study in a limited group of highly sensitized kidney patients using a surrogate endpoint. Results from this clinical

A new gas filling station opens in Mariestad, Sweden to further expand the Nordic network

The Nordic gas filling station network continues its rapid growth as energy company Gasum opens a new station in Mariestad, Sweden. This is Gasum’s seventh liquefied gas filling station for heavy-duty vehicles in Sweden, and the first Gasum filling station in Västra Götaland. This filling stations is a part of Gasum’s expanding network planning to have a network of 50 filling stations for heavy-duty vehicles by the early 2020s in the Nordics as the demand for cleaner fuel solutions continues to grow.The new gas filling station in Mariestad, Sweden will go into service on December 13. The

Enzymatica in agreement for enzyme formulations for the Chinese skin care market

Enzymatica’s subsidiary Zymetech has entered a non-exlusive agreement with Dr Bragi Company Ltd for the sales and delivery of three different enzyme formulations based on Enzymatica’s patented enzyme technology, which will be used in Dr Bragi Company’s skin care products. It is a five-year agreement covering China and parts of Asia. Dr Bragi Company has placed an initial order of about SEK 0.8 million for delivery at year-end  2019. Follow-up orders are expected in 2020. The agreement of formulations based on Enzymatica’s patented enzyme technology is the second agreement, after the agreement

Scott Rafkin appointed Volvo Group Chief Digital Officer

Scott Rafkin, currently President of Volvo Financial Services, has been appointed to the new position of Executive Vice President and Chief Digital Officer for the Volvo Group, effective January 1, 2020. In this role he will be a member of the Executive Board and report to the Volvo Group President and CEO Martin Lundstedt.Born in 1969, Scott Rafkin has served as President of Volvo Financial Services since 2014. He joined the Volvo Group in 2001 and has since held several managerial positions within Volvo Financial Services, including that of Chief Financial Officer.  As Chief Digital

Climeon completes Sea Trials with Virgin Voyages and Fincantieri

Climeon has successfully passed the SeaTrials for Virgin Voyages first ship, the Scarlet Lady.  At the end of 2017, Climeon passed the Factory Acceptance Test for the first order from Virgin Voyages and Fincantieri. Since then, the modules have been installed onboard Virgin Voyages first ship, the Scarlet Lady. Now another big milestone has been reached as the ship, including the Heat Power modules, has successfully completed the Sea Trials, where the ship is tested at sea for the first time. - This is a big milestone for Climeon, we have been working towards this goal for many years.

The TagMaster Nominating committee for 2020 is confirmed

Pressrelease, Stockholm, Sweden, December 13, 2019 The TagMaster Nominating committee for the AGM in April 2020 has been confirmed. Gert Sviberg, the company’s biggest shareholder, will be its chairman. Further members are Tomas Brunberg as the third biggest shareholder and Jean Francois Paumelle representing Eiffel Investment Group being the second biggest shareholder together with Marie-Louise Gefwert representing the smaller share holders and Rolf Norberg, chairman of the company. The Nominating committee has also decided to co-opt Didrik Hamilton being the fourth biggest shareholder.

CELLINK’s board has set financial targets for the company

CELLINK’s financial targets for the period 2019-2022 are as follows: CELLINK’s goal is to grow sales organically with a minimum of 35% per year and grow additionally through acquisitions. CELLINK’s Board targets a profitable growth, therefore CELLINK shall show a positive EBITDA margin during the period 2019-2022. CELLINK’s board considers that CELLINK should have a strong capital base in order to enable continued high growth, both organically and through acquisitions. The company’s net debt in relation to EBITDA should normally not exceed 3 times.  Goals in summary: · Organic

Bonava to donate SEK 250,000 to Doctors Without Borders

Bonava has chosen to donate this year’s Christmas gift of SEK 250,000 to Doctors Without Borders. Instead of giving out Christmas gifts to employees, Bonava has prioritised a donation to an organisation that helps people in need.– Instead of Christmas gifts to all our employees, we donated the money to people in need. Doctors Without Borders has great credibility and knowledge as regards tangible help for people in need. No-one can do everything, but everyone can do something, says Joachim Hallengren, President and CEO of Bonava. To decide who would receive the donation for 2019, Bonava

HKScan’s repurchases of own shares have been completed

HKScan Corporation, Stock Exchange Release, 13 December 2019, at 9:00 (EET)HKScan’s repurchases of own shares have been completed HKScan Corporation has completed the buy-back programme concerning the company’s own series A shares, the start of which was announced by the company on 25 September 2019. In trading organised by Nasdaq Helsinki Ltd, the company has between 1 October 2019 and 12 December 2019 acquired a total of 2 000 000 of its own series A shares with an average price of EUR 2.3614 per share. The total purchase price for the shares was EUR 4.7 million. On 13 December 2019,

Altor to divest Ålö to JOST

Altor Fund III (“Altor”), Fort Knox Förvaring AB and Management Investors have today signed an agreement to divest Ålö Holding AB (“Ålö”), a world leader within material handling solutions in the agricultural industry to JOST Werke AG (“JOST”). JOST is a world leading supplier of systems to the Truck and Trailer Industry.Ålö is a global market leader in top-quality front loaders and associated implements for agricultural tractors, with sales in more than 40 countries. Front loaders and implements are sold under the Quicke brand as well as in cooperation with tractor OEMs. The company has

New environmentally friendly barrier paper for food packaging

Paper based packaging that is used in bakeries, food outlets and quick service restaurants (QSR) often contains a treatment of a non-decomposable high-fluorinated chemical, known as PFAS.  Now BillerudKorsnäs is launching Repel Pure, a paper where the grease-resistant barrier is plant-based and totally biological.“Today we see an increasing demand for alternatives to PFAS treated products.  After working a long time to find a sustainable alternative to surface treatment with high-fluorinated substances, we are today very proud to present our paper Repel Pure,” says Helene Biström, Executive

Change in Kesko’s Group Management Board

Kesko Corporation is reorganising its Legal Affairs function. Lasse Luukkainen, Master of Laws, 41, has been appointed Kesko’s Group General Counsel as of 1 January 2020. He will also act as Company Secretary for Kesko's Board of Directors and its Committees and the Group Management Board. Luukkainen has worked at Kesko Corporation in various legal positions since 2010, most recently as Senior Corporate Counsel for Kesko’s grocery trade and Secretary to Group Management Board. Luukkainen will report to President and CEO Mikko Helander. Kesko’s current Group General Counsel and member of

Granted NOK 37.6 million to deliver hydrogen to ferries and cruise ships in the Geirangerfjord

Geirangerfjord image [Photo: Per_Eide] Photo: Per_Eide The Hellesylt Hydrogen Hub, a consortium of leading players in the hydrogen field, including Hexagon, has been awarded NOK 37.6 million under the PILOT-E funding scheme for the development of a hydrogen production facility that can deliver hydrogen to ferries and cruise ships in the Geirangerfjord, as well as to other mobility applications. The ambition is to achieve zero-emission operations in the Geirangerfjord, one of two World Heritage Fjords in Norway, by producing green hydrogen locally. See attached press release by

Fastpartner raises SEK 714 million in equity

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, CANADA, NEW ZEELAND, JAPAN, SWITZERLAND, OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. ADDITIONAL RESTRICTIONS ARE APPLICABLE. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT.Fastpartner AB (publ) (“Fastpartner”) has issued 8,500,000 common shares of series D. The price in the offer was set to SEK 84 per D-share following a book building process.

New free Expeditions mode now available for critically acclaimed "Control"

Remedy Entertainment Plc | Press release 7:45 am (EET) 13 December 2019 2019 Game of the Year (IGN, Official PlayStation Magazine) and Winner of Best Art Direction from The Game Awards Releases Free December Update on All Platforms for the Supernatural Action-Adventure Game Watch the Game Awards Trailer Here: youtu.be/voko5U5lGFU Global videogame publisher 505 Games  and its partner, internationally renowned developer Remedy Entertainment , have released a free December update for the third-person action-adventure game Control (

Ethical Trading Initiative is founded in Sweden

Swedish companies, trade unions, civil society organizations and authorities are now coming together to promote better working conditions and human rights in producing countries. The formation of a Swedish Ethical Trading Initiative, ETI Sweden, signifies a vigorous joint effort for fair conditions in world trade and business operations. ETI organizations are already established in the UK, Norway and Denmark. The Swedish counterpart is now gearing up to become an engine for better working conditions through cross-sectoral collaborations in Sweden. “It’s very gratifying! There is a

IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL PURSUANT TO APPLICABLE RULES OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. The board of directors of IRLAB Therapeutics AB (publ) (the “Company” or “IRLAB”) has, based on the authorization granted by the annual general meeting on 25 April 2019, resolved to carry out a directed issue of new shares of series A of approximately SEK 70 million to

Final result of SBB’s rights issue

Read more at: http://www.sbbnordeninfo.se/ For additional information, please contact: Ilija Batljan, CEO and Founder of Samhällsbyggnadsbolaget i Norden AB, +46 70 518 39 67, ilija@sbbnorden.se The information was sent for publication, through the agency of the contact person set out above, on December 12, 2019, at 22:00 (CET). About Samhällsbyggnadsbolaget i Norden AB (publ) The company’s strategy is to own, manage and develop community service properties throughout the Nordic region and rental apartments in growth regions in Sweden. Through the company's commitment and

Significant effect of Diamyd[®] in Type 1 diabetes shown in a new comprehensive analysis of previous Phase III and Phase II trials

Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and US with the diabetes vaccine Diamyd[® ]has identified genetically defined subgroups of type 1 diabetes patients that show a positive and statistically significant dose-dependent treatment response.In the analysis, patients who were positive for certain HLA genotypes and treated with the highest number of doses of Diamyd® (three and four subcutaneous injections) experienced a statistically significant treatment effect of approximately 60%

There are no items matching the current filter
There are no more items matching the current filter
Back to top